Literature DB >> 1622163

Duration of rifampin chemoprophylaxis for contacts of patients infected with Haemophilus influenzae type B.

M Green1, K I Li, E R Wald, N Guerra, C Byers.   

Abstract

Rifampin is recommended as a prophylactic treatment for intimate contacts of young children who develop invasive infections with Haemophilus influenzae type B (Hib). A 4-day course of rifampin (20 mg/kg of body weight per day, not to exceed 600 mg as a maximum single daily dose) is 95% effective in eradicating pharyngeal colonization with Hib, thus effectively reducing the risk of both associated patients and recurrent illness in index patients less than 2 years old. This study compares rates of eradication of pharyngeal colonization with Hib for 2- and 4-day courses of rifampin therapy. One hundred sixty-three patients with Hib infection were treated at Children's Hospital of Pittsburgh between January 1986 and December 1988; prophylaxis was recommended for 128. Participating families were randomized to receive either 2- or 4-day therapy. Throat swabs were obtained from contacts prior to therapy. Repeat cultures were obtained from colonized contacts 2 days after completing rifampin and again on all contacts 7 to 10 days after completing therapy. Of 68 participating families, 34 received 2-day and 34 received 4-day therapy with rifampin. Twenty-two of 24 colonized contacts in the 2-day group and 17 of 18 in the 4-day group had negative cultures for Hib on follow-up. Two-day therapy with rifampin appears to be as effective as 4-day treatment in the eradication of Hib pharyngeal colonization.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1622163      PMCID: PMC190554          DOI: 10.1128/AAC.36.3.545

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Use of rifampin in Haemophilus influenzae type b infections.

Authors:  K I Li; E R Wald
Journal:  Am J Dis Child       Date:  1986-04

Review 2.  Compliance with pediatric therapy. A selective review and recommendations.

Authors:  J G Jones
Journal:  Clin Pediatr (Phila)       Date:  1983-04       Impact factor: 1.168

Review 3.  Spread of Haemophilus influenzae type b: recent epidemiologic and therapeutic considerations.

Authors:  D M Granoff; R S Daum
Journal:  J Pediatr       Date:  1980-11       Impact factor: 4.406

4.  Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection.

Authors:  J W Hay; R S Daum
Journal:  Pediatrics       Date:  1987-09       Impact factor: 7.124

5.  Effect of rifampin chemoprophylaxis on carriage eradication and new acquisition of Haemophilus influenzae type b in contacts.

Authors:  M P Glode; R S Daum; E G Boies; T L Ballard; M Murray; D M Granoff
Journal:  Pediatrics       Date:  1985-10       Impact factor: 7.124

6.  Prevention of Hemophilus influenzae type b disease.

Authors:  J D Band; D W Fraser; G Ajello
Journal:  JAMA       Date:  1984-05-11       Impact factor: 56.272

7.  Gaps in doctor-patient communication. Patients' response to medical advice.

Authors:  V Francis; B M Korsch; M J Morris
Journal:  N Engl J Med       Date:  1969-03-06       Impact factor: 91.245

8.  Secondary Haemophilus influenzae type b in day-care facilities. Risk factors and prevention.

Authors:  D W Fleming; M H Leibenhaut; D Albanes; S L Cochi; A W Hightower; S Makintubee; S D Helgerson; C V Broome
Journal:  JAMA       Date:  1985-07-26       Impact factor: 56.272

9.  Rifampin chemoprophylaxis for household contacts of patients with invasive infections due to Haemophilus influenzae type b.

Authors:  R S Daum; M P Glode; D A Goldmann; N Halsey; D Ambrosino; C Welborn; F J Mather; J E Willard; B Sullivan; M Murray; T Johansen
Journal:  J Pediatr       Date:  1981-03       Impact factor: 4.406

10.  Efficacy of rifampin in eliminating pharyngeal carriage of Haemophilus influenzae type b.

Authors:  E D Shapiro; E R Wald
Journal:  Pediatrics       Date:  1980-07       Impact factor: 7.124

View more
  1 in total

1.  Haemophilus influenzae: then and now.

Authors:  J Z Jordens; M P Slack
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.